Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51

Leukemia and Lymphoma

Volumn 48, Issue 7, 2007, Pages 1290-1298

  Kurtz, David M ^a   Tschetter, Loren K ^b   Allred, Jacob B ^a   Geyer, Susan M ^a   Kurtin, Paul J ^a   Putnam, Wesley D ^b   Rowland Jr , Kendrith M ^c   Wiesenfeld, Martin ^d   Soori, Gamini S ^e   Tenglin, Richard C ^f   Bernath, Albert M ^g   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

^b Sioux Community Cancer Consortium   (United States)

^c Carle Cancer Center   (United States)

^d CCOP   (United States)

^e MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^f Rapid City Regional Oncology Group   (United States)

^g GEISINGER MEDICAL CENTER   (United States)

Author keywords

Interleukin 4; Non Hodgkin lymphoma; Signal transducer activator of transcription 6

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; LIVER ENZYME;

ADULT; AGED; ANOREXIA; ARTICLE; ASCITES; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CANCER GROWTH; CANCER RELAPSE; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; EDEMA; FACE EDEMA; FEMALE; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LOW DRUG DOSE; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-4; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34447553509     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701355028     Document Type: Article

References (44)

1. Howe, H. L., Ries, L. A., Cokkinides, V., Ahmed, F. and Jemal, A. (2006) Annual report to the nation on the status of cancer, 1975 - 2003, featuring cancer among U.S. hispanic/latino populations. Cancer, 107, pp. 1711-1742.
2. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E. and Catalano, J. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, pp. 1417-1423.
3. Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A. and Cohn, J. B. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol, 24, pp. 3121-3127.
4. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. and Bouabdallah, R. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
5. Nelms, K., Keegan, A. D., Zamorano, J., Ryan, J. J. and Paul, W. E. (1999) The IL-4 receptor: Signaling mechanisms and biologic functions. Annu Rev Immunol, 17, pp. 701-738.
6. Jiang, H., Harris, M. B. and Rothman, P. (2000) IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol, 105, pp. 1063-1070.
7. Kriegel, M. A., Tretter, T., Blank, N., Schiller, M., Gabler, C. and Winkler, S. (2006) Interleukin-4 supports interleukin-12-induced proliferation and interferon-gamma secretion in human activated lymphoblasts and T helper type 1 cells. Immunology, 119, pp. 43-53.
8. Leonard, W. J., Noguchi, M. and Russell, S. M. (1994) Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: implications for X-linked severe combined immunodeficiency (XSCID). Adv Exp Med Biol, 365, pp. 225-232.
9. Obiri, N. I., Debinski, W., Leonard, W. J. and Puri, R. K. (1995) Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem, 270, pp. 8797-8804.
10. Murata, T., Taguchi, J. and Puri, R. K. (1998) Interleukin-13 receptor alpha' but not alpha chain: A functional component of interleukin-4 receptors. Blood, 91, pp. 3884-3891.
11. Obiri, N. I., Hillman, G. G., Haas, G. P., Sud, S. and Puri, R. K. (1993) Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest, 91, pp. 88-93.
12. Topp, M. S., Papadimitriou, C. A., Eitelbach, F., Oelmann, E., Koehler, B. and Oberberg, D. (1995) Antiproliferative effect of human interleukin-4 in human cancer cell lines: Studies on the mechanism. Leuk Lymphoma, 19, pp. 319-328.
13. Gooch, J. L., Lee, A. V. and Yee, D. (1998) Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res, 58, pp. 4199-4205.
14. Topp, M. S., Papadimitriou, C. A., Eitelbach, F., Koenigsmann, M., Oelmann, E. and Koehler, B. (1995) Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res, 55, pp. 2173-2176.
15. Lahm, H., Schnyder, B., Wyniger, J., Borbenyi, Z., Yilmaz, A. and Car, B. D. (1994) Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors. Int J Cancer, 59, pp. 440-447.
16. Toi, M., Bicknell, R. and Harris, A. L. (1992) Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res, 52, pp. 275-279.
17. Crawford, R. M., Finbloom, D. S., Ohara, J., Paul, W. E. and Meltzer, M. S. (1987) B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. J Immunol, 139, pp. 135-141.
18. Mule, J. J., Smith, C. A. and Rosenberg, S. A. (1987) Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med, 166, pp. 792-797.
19. Tepper, R. I., Pattengale, P. K. and Leder, P. (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell, 57, pp. 503-512.
20. Manabe, A., Coustan-Smith, E., Kumagai, M., Behm, F. G., Raimondi, S. C. and Pui, C. H. (1994) Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood, 83, pp. 1731-1737.
21. Schnyder, B., Lahm, H., Woerly, G., Odartchenko, N., Ryffel, B. and Car, B. D. (1996) Growth inhibition signalled through the interleukin-4/ interleukin-13 receptor complex is associated with tyrosine phosphorylation of insulin receptor substrate-1. Biochem J, 315, pp. 767-774.
22. Jackson, J. G., White, M. F. and Yee, D. (1998) Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem, 273, pp. 9994-10003.
23. Gooch, J. L., Christy, B. and Yee, D. (2002) STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia, 4, pp. 324-331.
24. Todaro, M., Zerilli, M., Ricci-Vitiani, L., Bini, M., Alea, M Perez and Florena, A Maria (2006) Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res, 66, pp. 1491-1499.
25. Schwarz, M. A., Tardelli, L., Macosko, H. D., Sullivan, L. M., Narula, S. K. and Fine, J. S. (1995) Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res, 55, pp. 3692-3696.
26. Defrance, T., Fluckiger, A. C., Rossi, J. F., Magaud, J. P., Sotto, J. J. and Banchereau, J. (1992) Antiproliferative effects of interleukin-4 on freshly isolated non-Hodgkin malignant B-lymphoma cells. Blood, 79, pp. 990-996.
27. Taylor, C. W., Grogan, T. M. and Salmon, S. E. (1990) Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood, 75, pp. 1114-1118.
28. Taylor, C. W., LeBlanc, M., Fisher, R. I., Moore Sr, D. F., Roach, R. W. and Elias, L. (2000) Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: A Southwest Oncology Group trial. Anticancer Drugs, 11, pp. 695-700.
29. Fabre-Guillevin, E., Tabrizi, R., Coulon, V., Monnereau, A., Eghbali, H. and Soubeyran, I. (2006) Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma, 47, pp. 603-611.
30. Kaplan, M. H., Daniel, C., Schindler, U. and Grusby, M. J. (1998) Stat proteins control lymphocyte proliferation by regulating p27Kip1 expression. Mol Cell Biol, 18, pp. 1996-2003.
31. Hu, Z. Q., Zhao, W. H., Shimamura, T. and Galli, S. J. (2006) Interleukin-4-triggered, STAT6-dependent production of a factor that induces mouse mast cell apoptosis. Eur J Immunol, 36, pp. 1275-1284.
32. Pircher, T. J., Petersen, H., Gustafsson, J. A. and Haldosen, L. A. (1999) Extracellular signal-regulated kinase (ERK) interacts with signal transducer and activator of transcription (STAT) 5a. Mol Endocrinol, 13, pp. 555-565.
33. Al-Shami, A. and Naccache, P. H. (1999) Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase. J Biol Chem, 274, pp. 5333-5338.
34. Gollob, J. A., Schnipper, C. P., Murphy, E. A., Ritz, J. and Frank, D. A. (1999) The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol, 162, pp. 4472-4481.
35. David, M., Ford, D., Bertoglio, J., Maizel, A. L. and Pierre, J. (2001) Induction of the IL-13 receptor alpha2-chain by IL-4 and IL-13 in human keratinocytes: Involvement of STAT6, ERK and p38 MAPK pathways. Oncogene, 20, pp. 6660-6668.
36. Lossos, I. S., Alizadeh, A. A., Rajapaksa, R., Tibshirani, R. and Levy, R. (2003) HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood, 101, pp. 433-440.
37. Nechushtan, H., Ding, F., Rosado, M. F., Singal, R. and Alizadeh, A. A. (2005) Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. Blood, 105, pp. 2924-2932.
38. Lossos, I. S. (2005) Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol, 23, pp. 6351-6357.
39. Nechushtan, H., Rosenblatt, J. D. and Lossos, I. S. (2004) IL-4 affects proliferation, chemosensitivity-and rituximab sensitivity of germinal center B-cell like (GCB) and activated B-cell like (ABC) diffuse large B-cell lymphoma differently. ASH Annu Meet Abstr, 104, p. 242.
40. Sasaki, Y., Mita, H., Toyota, M., Ishida, S., Morimoto, I. and Yamashita, T. (2003) Identification of the interleukin 4 receptor alpha gene as a direct target for p73. Cancer Res, 63, pp. 8145-8152.
41. Husain, S. R., Kreitman, R. J., Pastan, I. and Puri, R. K. (1999) Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med, 5, pp. 817-822.
42. Joshi, B. H., Leland, P., Silber, J., Kreitman, R. J., Pastan, I. and Berger, M. (2002) IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein. Br J Cancer, 86, pp. 285-291.
43. Kawakami, K., Kawakami, M. and Puri, R. K. (2001) Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol, 21, pp. 299-310.
44. Kay, N. E., Bone, N. D., Lee, Y. K., Jelinek, D. F., Leland, P. and Battle, T. E. (2005) A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. Leuk Res, 29, pp. 1009-1018.